Bortezomib and dexamethasone, an original approach for treating multi‐refractory warm autoimmune haemolytic anaemia. (2nd June 2019) - Fadlallah, Jehane
Summary: We report the off‐label use of bortezomib combined with dexamethasone in eight adults with severe and multi‐refractory warm auto‐immune haemolytic anaemia (wAIHA). After six cycles of induction therapy, 6 of the 8 patients achieved response (3 complete response, 3 response). Response was obtained after a median of 2 (1–4) cycles. After a median follow‐up of 14 (6–36) months, six patients maintained a response (bortezomib/dexamethasone maintenance, n = 4); five patients experienced at least one moderate adverse event, including peripheral neuropathy ( n = 2). These results suggest that bortezomib/dexamethasone combination is a promising approach with acceptable toxicity for treating severe refractory wAIHA in adults.